IPIX MM Monthly ~ May 2018 May 2018 ~

New Post Public Reply Private Reply Replies (1) Message Board
4kids 4kids #3685
251
IPIX MM Monthly ~ May 2018







May 2018 ~ volume total ~ 5,542,951

April 2018 MM Monthly link:
https://investorshangout.com/post/view?id=5033179


there were 11 MMs/ECNs' reporting *activity* on IPIX .. in order:
ETRF/NITE/CDEL (32%/23%/22%)
CSTI/LAFC/ARCA/OTCX/VERT (5%/4%/4%/4%/3%)
CANT/MAXM/PUMA .. all less then 1%

amazing how much of a *decoy* both VERT & OTCX *were* ..

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 ETRF G1 EXECUTION SVCs, LLC 1,779,590 1 32.11
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 NITE VIRTU AMERICAS LLC 1,288,265 2 23.24
IPIX Innovation Pharma 5,542,951 4,473,436 22,616,572 CDEL CITADEL SECURITIES LLC 1,224,386 3 22.09


it's been just about a year since mgmt's upside surprise in June 2017 .. here's the Monthly Volume Totals broken down by month .. take note of the *overlapping* similarities

JUN 2017 ~ 6,863,055
JUL 2017 ~ 4 ,896,207
AUG 2017 ~ 3 ,276,355
SEP 2017 ~ 2,395,379
OCT 2017 ~ 3 ,856,915
NOV 2017 ~ 4,0 31,082
DEC 2017 ~ 8,121,069
JAN 2018 ~ 5 ,133,221
FEB 2018 ~ 3 ,388,387
MAR 2018 ~ 4,0 78,577
APR 2018 ~ 4 ,473,436
MAY 2018 ~ 5 ,542,951

http://otce.finra.org/MonthlyShareVolume

during that same year long period .. *legal* had to be adjusted *upward* ..
(see below) .. but first .. i pulled the data (historical .. pps and volume avgs) from mid month for the last year >> to show patterns done on IPIX ..

5.15.17 ( markage @ 41% )
Detailed Quote:CTIX
CELLCEUTIX CORPORATION
0.82825Up 0.11825 (16.65 %) AS OF 3:58:26PM ET 05/15/2017


Volume 547,948
Volume (10 day Average) 140,183
Volume (90 day Average) 278,946


6.15.17 ( markage @ 24% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.76Up 0.02 (2.70 %)AS OF 3:57:28PM ET 06/15/2017


Volume 224,876
Volume (10 day Average) 336,072
Volume (90 day Average) 267,023


7.17.17 ( markage @ 23% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.972Down -0.068 (-6.54 %) AS OF 3:59:15PM ET 07/17/2017


Volume 249,885
Volume (10 day Average) 286,095
Volume (90 day Average) 276,468


8.15.17 ( markage @ 27% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.785Up 0.0565 (7.76 %) AS OF 3:57:24PM ET 08/15/2017


Volume 76,529
Volume (10 day Average) 161,964
Volume (90 day Average) 268,908


9.15.17 ( markage @ 22% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.72Up 0.0095 (1.34 %) AS OF 3:59:51PM ET 09/15/2017


Volume 223,443
Volume (10 day Average) 100,122
Volume (90 day Average) 227,459


10.16.17 ( markage @ 38% ) .. cracks starting to *show* (see below)
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.68Down -0.01 (-1.45 %) AS OF 3:59:59PM ET 10/16/2017


Volume 113,405
Volume (10 day Average) 168,465
Volume (90 day Average) 197,664


11.15.17 ( markage @ 15% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.69Down -0.015 (-2.13 %) AS OF 3:59:04PM ET 11/15/2017


Volume 163,194
Volume (10 day Average) 172,115
Volume (90 day Average) 164,764


12.15.17 ( markage @ 26% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.785Up 0.00705 (0.91 %) AS OF 3:59:57PM ET 12/15/2017


Price Performance (Last 52 Weeks)
12/14/2017 -32.35%


Volume 153,680
Volume (10 day Average) 563,214
Volume (90 day Average) 202,489


1.16.18 ( markage @ 32% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.7249Up 0.0149 (2.10 %) AS OF 3:59:25PM ET 01/16/2018


Price Performance (Last 52 Weeks)
01/12/2018 -39.06%


Volume 300,052
Volume (10 day Average) 244,424
Volume (90 day Average) 224,823


2.15.18 ( markage @ 36% ) ** 52 week low reset 2.22.18 (5.10.17)
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.69Up 0.005 (0.73 %) AS OF 3:56:07PM ET 02/15/2018


Price Performance (Last 52 Weeks)
02/14/2018 -31.50%


Volume 115,948
Volume (10 day Average) 159,451
Volume (90 day Average) 243,268


3.15.18 ( markage @ 27% )
DETAILED QUOTE:IPIX
INNOVATION PHARMACEUTICALS INC
0.57Down -0.03 (-5.00 %) AS OF 3:55:43PM ET 03/15/2018


PRICE PERFORMANCE (LAST 52 WEEKS)
03/14/2018 -35.48%


VOLUME 329,874
VOLUME (10 DAY AVERAGE) 210,605
VOLUME (90 DAY AVERAGE) 251,097


4.16.18 ( markage @ 57% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.50Down -0.007 (-1.38 %) AS OF 3:59:59PM ET 04/16/2018


Volume 295,972
Volume (10 day Average) 151,331
Volume (90 day Average) 243,964


5.15.18 ( markage @ 50% )
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.59005Up 0.15405 (35.33 %) AS OF 3:59:48PM ET 05/15/2018


Volume 384,483
Volume (10 day Average) 335,770
Volume (90 day Average) 218,697



===========================================

*legal* reported by NR on CTIX/IPIX since Jan 2017 ~ remember NR reset 52 week low on IPIX on 5.10.17 .. approx 1 month later mgmt did a *surprise* to NR by changing out name/ticker and cusip .. which took NR until 2.22.18 to *reset* ..

spot the *pattern* NR deployed on IPIX re: their *reporting* .. .. and note the whoppers' reported re: avg daily volume by NR .. Dec 2017 (among other months) comes to mind .. btw that *reporting* would *impact* those *days to cover* also *reported* by NR .. go figure



Settlement Date
Issue Name
Symbol
Market
Current Short
Previous Short
Chg
% Change from Prev
Avg Daily Vol
Days to Cover

 
05/15/2018 Innovation Pharma IPIX 1,194,881 1,113,653 81,228 7.29 677,661 1.76
04/30/2018 Innovation Pharma IPIX 1,113,653 1,131,509 -17,856 -1.58 536,933 2.07
04/13/2018 Innovation Pharma IPIX 1,131,509 1,105,305 26,204 2.37 302,523 3.74
03/29/2018 Innovation Pharma IPIX 1,105,305 1,107,705 -2,400 -0.22 328,260 3.37
03/15/2018 Innovation Pharma IPIX 1,107,705 1,146,037 -38,332 -3.34 442,762 2.5
02/28/2018 Innovation Pharma IPIX 1,146,037 1,147,767 -1,730 -0.15 419,357 2.73
02/15/2018 Innovation Pharma IPIX 1,147,767 1,122,033 25,734 2.29 310,620 3.7
01/31/2018 Innovation Pharma IPIX 1,122,033 1,121,161 872 0.08 494,222 2.27
01/12/2018 Innovation Pharma IPIX 1,121,161 1,119,374 1,787 0.16 479,712 2.34
12/29/2017 Innovation Pharma IPIX 1,119,374 1,125,087 -5,713 -0.51 517,994 2.16
12/15/2017 Innovation Pharma IPIX 1,125,087 1,129,343 -4,256 -0.38 1,046,247 1.08
11/30/2017 Innovation Pharma IPIX 1,129,343 1,140,375 -11,032 -0.97 428,497 2.64
11/15/2017 Innovation Pharma IPIX 1,140,375 1,274,605 -134,230 -10.53 342,258 3.33
10/31/2017 Innovation Pharma IPIX 1,274,605 1,227,218 47,387 3.86 361,557 3.53
10/13/2017 Innovation Pharma IPIX 1,227,218 1,214,663 12,555 1.03 335,578 3.66
09/29/2017 Innovation Pharma IPIX 1,214,663 1,214,089 574 0.05 262,229 4.63
09/15/2017 Innovation Pharma IPIX 1,214,089 1,220,108 -6,019 -0.49 215,861 5.62
08/31/2017 Innovation Pharma IPIX 1,220,108 1,226,343 -6,235 -0.51 262,819 4.64
08/15/2017 Innovation Pharma IPIX 1,226,343 1,206,257 20,086 1.67 307,793 3.98
07/31/2017 Innovation Pharma IPIX 1,206,257 1,302,241 -95,984 -7.37 389,777 3.09
07/14/2017 Innovation Pharma IPIX 1,302,241 1,458,432 -156,191 -10.71 609,859 2.14
06/30/2017 Innovation Pharma IPIX 1,458,432 1,234,237 224,195 18.16 594,048 2.46
06/15/2017 Innovation Pharma IPIX 1,234,237 1,161,877 72,360 6.23 650,213 1.9

05/31/2017 Cellceutix CTIX 1,161,877 1,037,384 124,493 12 579,670 2.0

 
May 15, 2017 1,037,384 18.46 354,459 2.93 No No
Apr 28, 2017 875,733 -0.07 759,565 1.15 No No
Apr 13, 2017 876,376 3.15 558,853 1.57 No No
Mar 31, 2017 849,619 -1.16 492,310 1.73 No No
Mar 15, 2017 859,596 -2.21 297,012 2.89 No No
Feb 28, 2017 879,016 0.82 796,211 1.10 No No
Feb 15, 2017 871,870 -0.34 373,962 2.33 No No
Jan 31, 2017 874,870 11.57 1,079,666 1.00 No No
Jan 13, 2017 784,114 -1.41 390,950 2.01 No No


NR had worked the cycle of money on CTIX (IPIX) *UP/DOWN* for years .. and most likely figured in early Jan 2015 .. that flip *DOWN* would be no different .. but a funny thing happened .. due to mgmt's ability to execute .. actual investors couldn't be parted from their *shares* and it set up *imo* the *events* by NR in the latter half of 2015 .. which mgmt didn't roll over for .. rather *aggressively responded* to .. and so it's gone since then .. this is why i note that NR is in a hole of their own making .. NR is used to always controlling *outcomes* on the OTC .. right now they have little time and imo even less *liquidity* .. which is why i say they are stuck .. and their *stuckness* is telegraphing itself via a *legal* that is almost amusing to watch *reported* .. bogus daily volume avgs reported re: that *legal* .. and daily *markages* ( % wise ) that keep ratcheting northward .. all this on less and less *volume* .. oh yeah and Innovation's multi platform hanging over NRs' *head* like the sword of damocles .. it couldn't happen to a nicer group of crooks *imo*

in pulling this post together (always time consuming) .. i realized i have the *legal reported* .. since Innovation first started trading .. way back when ..

if i have the time i will try and get that out sometime this week .. it's amazing how NRs' *cycles of money* .. worked for them so well for so long .. but nothing beats an aware OTC mgmt team that executes and an educated retail investor ..

best to all Innovation Pharma investors

4kids

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

Updated Category News Views 3

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Continue Reading
Cala Launches Game-Changer Wearable for Tremor Relief

Updated Category News Views 10

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Continue Reading
Truss Financial Tackles Home Equity Closing Delays

Updated Category News Views 8

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Continue Reading
NYSE Texas Redefines the U.S. Capital Markets Landscape

Updated Category News Views 10

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

Continue Reading
Northern Jet Names Veteran Matthew Harris as CEO

Updated Category News Views 20

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Continue Reading
Community Banks Missing $106B Lending Opportunity?

Updated Category News Views 6

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Continue Reading
Pushing for National Liver Cancer Awareness in 2026

Updated Category News Views 6

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Continue Reading
JiMMYBAR! Expands Creatine Market with Target Launch

Updated Category News Views 10

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...

Continue Reading
ROKFORM’s Signal Card: A Wallet Tracker for All

Updated Category News Views 7

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Continue Reading
Epic Political Thriller Explores Humanity's Future

Updated Category News Views 4

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Continue Reading

Top 5 Most Recently Viewed Articles

Thermo Fisher Scientific Reports Steady Q3 Performance

Updated Category News Views 69

Thermo Fisher Scientific's Q3 Performance Overview Thermo Fisher Scientific Inc. (NYSE: TMO) recently shared its financial results for the third quarter, revealing revenue of approximately $10.59 billion. While this figure is nearly unchanged compared to the previous year, it slightly fell short of the anticipated consensus of $10.64 billion. Segment Performance Analysis...

Continue Reading
Consumer Insights and Retail Earnings: Navigating New Trends

Updated Category News Views 213

Examining Retail Earnings and Consumer Sentiment This week marks a significant moment for the retail industry as key players prepare to unveil their earnings reports. The anticipation builds as we await insights from top retailers this week. Recently, the U.S. Census Bureau shared insights on retail sales, revealing mixed results. While the figures aren’t staggering,...

Continue Reading
Surge Copper Corp. Delivers Long-Term Equity Incentives to Team

Updated Category News Views 157

Surge Copper Corp. Grants Equity-Based Incentives Surge Copper Corp. (TSXV: SURG) is excited to announce a significant development in its incentive program aimed at enhancing team engagement. As part of its Share Compensation Plan, the Company has awarded a substantial number of long-term equity-based incentive awards to its dedicated employees and executives. Details of...

Continue Reading
Stepan Company Welcomes New Leadership in Finance

Updated Category News Views 204

Stepan Company Welcomes New Vice President and CFO Stepan Company, a leader in the specialty and intermediate chemicals sector, proudly announces the appointment of Ruben Velasquez as their new Vice President and Chief Financial Officer. This significant move signifies Stepan's commitment to strengthening its financial leadership. Mr. Velasquez's role becomes effective...

Continue Reading
Kiana Mehring Breaks Ground in Oncology Leadership

Updated Category News Views 9

Award-Winning Leadership in Oncology In the world of oncology, it's not every day that you see a young leader make waves like Kiana Mehring from Florida Cancer Specialists & Research Institute (FCS). This lady just nabbed the 40 Under 40 in Cancer Award, shining a light on the complicated dance of payer strategies and patient care. Recognizing folks like Mehring, who’s...

Continue Reading